Evaluation of the application for registration of circulation of the Nanocovax vaccine produced by President Ho Nhan’s Nanogen
Specifically, considering the report of the Ministry of Health on the results of reviewing the application for a certificate of circulation of the Covid-19 vaccine Nanocovax registered and manufactured by Nanogen Pharmaceutical Biotechnology Joint Stock Company, Deputy Prime Minister Prime Minister Vu Duc Dam requested the Ministry of Health to urgently implement the Prime Minister’s direction in Document No. 1027/2022 of the Government Office and other relevant documents; continue to guide and support enterprises in all cases as prescribed by law.
Previously, according to document No. 1027/2022 of the Government Office, Nanogen Pharmaceutical Biotechnology Joint Stock Company sent a document to the Prime Minister proposing to consider the application for a license to circulate the Nanocovax vaccine.
Regarding this, Prime Minister Pham Minh Chinh requested the Ministry of Health to consider and handle the request of Nanogen Pharmaceutical Biotechnology Joint Stock Company in accordance with its competence and regulations; ensure safety, science and minimize administrative procedures.
The Government Office shall notify the Ministry of Health and relevant agencies for implementation. Nanocovax is a Covid-19 vaccine candidate researched and developed by Vietnam’s Nanogen Company since May 2020, based on recombinant protein technology.
Before the phase 3 trial, this vaccine has undergone 2 phases of clinical trials: Phase 1 starting from December 18, 2020, phase 2 from February 26, 2021 and phase 3 officially from 11/6/2021.
According to the approved outline, phase 3 of the Nanocovax vaccine trial was administered to evaluate the protective effect of the vaccine on the community and was carried out at many centers in the country with 13,000 people; Only the 25 mcg dose group and the placebo group were administered.
In August 2021, Korea Times reported, HLB Pharmaceutical Company (Korea) signed a memorandum of understanding (MOU) with Nanogen to buy the right to supply Nanocovax vaccine globally, except in Vietnam and India. .
Mr. Ho Nhan, Chairman and CEO of Nanogen also said: “Vietnam is the fourth vaccine producer in Asia, with a history of 126 years of vaccine development. We highly appreciate the previous experiences of HLB in this bioindustry”. The Chairman and CEO of Nanogen is Mr. Ho Nhan, a scientist born in 1966 who obtained a doctorate in biotechnology in the US.
One of the largest pharmaceutical companies in India, Vekaria Pharmaceutical Group, signed an agreement with Nanogen earlier this month to supply Nanocovax to the world’s second most populous country.
at Blogtuan.info – Source: cafebiz.vn – Read the original article here
